Section
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.
The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.
ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psor
The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.
This systematic review highlights patient and caregiver priorities in chronic urticaria treatment, emphasizing rapid symptom relief, long-term effectiveness, and safety.
AI demonstrates high accuracy in identifying mpox and other anogenital conditions from clinical images, yet significant research gaps and validation needs remain before clinical adoption.
A recent survey reveals that Australian dermatologists are cautiously integrating AI into practice, prioritizing accuracy and trust for diagnostic use, with optimism about AI enhancing patient access and reducing workload but concerns about
A 16-week Mediterranean diet intervention significantly reduced psoriasis severity and improved metabolic markers in patients with mild to moderate disease, suggesting diet’s role as adjunctive therapy in psoriasis management.
In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psorias
A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.
Patients with hidradenitis suppurativa face a higher risk of first-time depression and anxiety, regardless of disease severity, highlighting the need for comprehensive psychiatric care.
A large pragmatic trial demonstrates that daily emollient application starting before 9 weeks of age significantly reduces the risk of atopic dermatitis by 24 months in infants not selected for high risk, offering a feasible preventive appr
Patients with hidradenitis suppurativa face a significantly increased risk of new-onset depression and anxiety, independent of disease severity, highlighting the need for universal psychiatric assessment in this population.
This article evaluates the prevalence and infection risks associated with combination targeted therapies in adults with psoriatic arthritis, revealing no significant increase in serious or opportunistic infections compared to standard thera
A national database study finds no significant increase in early major adverse cardiovascular events (MACEs) after starting IL-17 inhibitors in psoriasis and related diseases, although a modest risk cannot be excluded.
A tick bite led to a severe illness requiring ICU care. Learn about the risks, symptoms, and crucial prevention measures to stay safe from tick-borne diseases.
A large retrospective cohort study identifies a significant association between alopecia areata and increased risks of microscopic colitis, celiac disease, Crohn’s disease, eosinophilic esophagitis, and ulcerative colitis, highlighting the
The gut-skin axis embodies a bidirectional microbiota-influenced dialogue pivotal for tissue homeostasis and disease. Understanding this interplay reveals innovative approaches to manage inflammatory skin and gut diseases.
A large retrospective study of over 524,000 patients found no increased risk of tachycardia associated with low-dose oral minoxidil (≤5 mg/day) for nonscarring hair loss, supporting its cardiac safety profile in patients without preexisting
